ecopipam + mefenamic acid

**ecopipam + mefenamic acid** is a combination of two pharmaceutical agents: - **Ecopipam** is a selective dopamine D1 and D5 receptor antagonist investigated for central nervous system disorders, most notably Tourette syndrome, Lesch–Nyhan syndrome, restless legs syndrome, and speech disorders. Its mechanism centers on antagonism of D1 family dopamine receptors, potentially reducing repetitive and compulsive behaviors in neuropsychiatric conditions. It is an orally active, synthetic benzazepine derivative with elimination half-life of about 10 hours. - **Mefenamic acid** is a nonsteroidal anti-inflammatory drug (NSAID) of the anthranilic acid class (a fenamate), primarily indicated for short-term treatment of mild-to-moderate pain, including dysmenorrhea. Its mechanism involves inhibition of cyclooxygenase (COX-1 and COX-2) enzymes, thereby blocking prostaglandin synthesis and mediating analgesic and anti-inflammatory effects. There is no specific evidence for the use or development of this exact combination for any medical condition.

Other names

N-(2,3-xylyl)-2-aminobenzoic acidN-2,3-xylylanthranilic acidAcide méfénamiqueácido mefenámicoAcidum mefenamicumMefenaminsäure